The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Real-world efficacy & safety of elranatamab in R/R myeloma: an IMWG immunotherapy database analysis
Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, discusses the real-world efficacy and safety of elranatamab, a BCMA-targeting bispecific antibody, in patients with relapsed/refractory (R/R) multiple myeloma, presenting data from an analysis of the International Myeloma Working Group (IMWG) immunotherapy database. The real-world data demonstrate response and progression-free survival (PFS) rates similar to those in the MagnetisMM-3 trial (NCT04649359), with the toxicity profile being as expected. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Elranatamab is a BCMA-targeted bispecific antibody that’s approved for patients with relapsed/refractory myeloma. It’s very important with these bispecific antibodies to understand how they function in the real world and at the moment there isn’t much data with elranatamab. So what I’m presenting here at ASH is a real-world data set from the International Myeloma Working Group...
Elranatamab is a BCMA-targeted bispecific antibody that’s approved for patients with relapsed/refractory myeloma. It’s very important with these bispecific antibodies to understand how they function in the real world and at the moment there isn’t much data with elranatamab. So what I’m presenting here at ASH is a real-world data set from the International Myeloma Working Group. The advantage of this data set is that it is truly international spanning both North America, the UK and Europe. We also hope to be bringing aboard the Asian countries and other international collaborators next year. But at the moment we’re reporting results of about 75 patients with relapsed myeloma globally. And actually, what was striking was that the data that we found is very similar to the Magnetism phase three clinical trial. So we’re seeing a response rate of 60 to 70 percent and our 12 and 18 month progression-free survival rates are in keeping with the Magnetism phase I trial, showing approximately a 12 to an 18-month progression-free survival rate. We’re seeing that the main toxicities are CRS, as expected, and we’re seeing a relatively low-grade level of grade 3 infections, mainly because of the use of IVIG, which was used in about 50% of patients. So overall, it was very encouraging, the real-world data with elranatamab, which is very similar to the Magnetism study data and showing this very strong, prolonged, progression-free survival with elranatamab.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
